Latest Breaking News On - Annika khine - Page 1 : comparemela.com

Dapagliflozin is cost-effective for chronic kidney disease compared with standard of care, in the UK, Germany, and Spain, despite the fact that the drug has high acquisition costs, finds a new analysis.

United statesUnited kingdomPhil mcewanLos angelesAnnika khineEugene linAmerican society of nephrologyDrug administrationUniversity of southern californiaAdverse outcomesAmerican societyClinical journalSouthern californiaMedical centerIncremental cost effectivenessNew england journal